Skip to main content


Ysios Capital Partners has announced that it has led a €2 million Series A investment in STAT-Diagnostica. This operation has included joint funding from the Spanish Official Credit Institute (ICO), FESpyme FCR, managed by Axis Participaciones Empresariales.

STAT-Diagnostica was founded in 2010 and is located in the bioincubator at the Barcelona Science Park (PCB). The company focuses on developing Point of Care clinical diagnostic systems, simplifying current procedures and reducing time to results compared to current diagnostic systems.

With this new injection of capital, STAT-Diagnostica will develop a new, easy-to-use in-vitro diagnostic platform, which will consolidate both molecular diagnostics and immunoassay capabilities in one system. Its main applications will be in the fields of infectious diseases, antibiotic resistance and measuring biomarkers in critical patients or emergency situations.

Raúl Martín-Ruiz, Ysios investment director: "This project fits with our investment philosophy. It covers an un-met medical need and will represent a benefit for the patient.”

The platform STAT is developing will allow for multi-analytical and multi-sample detection as well as a significant reduction in time to results, in some cases several days, one hour or even 15 minutes. “It will allow us to perform diagnostic tests close to the patient and obtain results in a short period of time. In addition, the simplicity of use, reliability and capacity to generate complementary analytical results will be key in helping physicians administer the most appropriate treatment from the very beginning for at-risk patients,” explains Jordi Carrera, managing director and co-founder of STAT-Diagnostica.

"This projects fits perfectly with our investment philosophy. It is addressed to a currently un-met medical need and its implementation will represent a benefit for patients and important savings for healthcare systems,” explains Raúl Martín-Ruiz, Ysios investment director. "The Point of Care diagnostics market is expected to grow significantly in the coming years and STAT-Diagnostica’s platform brings together a number of competitive advantages over products currently on the market and in development. These conditions, together with the founders’ experience and commitment, convinced us to carry out this investment,” says Martín-Ruiz.

With this investment in STAT-Diagnostica, Ysios Capital Partners has six investments in its portfolio.

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.